<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="362365">
  <stage>Registered</stage>
  <submitdate>11/04/2012</submitdate>
  <approvaldate>17/04/2012</approvaldate>
  <actrnumber>ACTRN12612000434897</actrnumber>
  <trial_identification>
    <studytitle>To compare the efficacy &amp; safety profile of Febuxostat with Allopurinol in 
local Pakistani hyperuricemic patients.</studytitle>
    <scientifictitle>Compare the Urate lowering response of Febuxostat &amp; Allopurinol in Hyperuricemic patients</scientifictitle>
    <utrn />
    <trialacronym>FASE</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hyperuricemia</healthcondition>
    <healthcondition>Gout</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Febuxostat 40-80 mg Tab Once daily (O.D.) oral, for 6 months

"The recommended starting dosage is 40 mg once daily. After two weeks, your healthcare provider should check your uric acid level (using a blood test). If your level is not sufficiently low (6 mg/dL or less), the dosage may be increased to 80 mg once daily."</interventions>
    <comparator>Allopurinol 100-300 mg tablet once daily (O.D.), Oral, for 6 months

"Initial: 100 mg orally once a day.
Maintenance: 200 to 300 mg (mild gout) orally once a day or 400 to 600 mg/day (moderately severe tophaceous gout) in divided doses."</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Compare the Urate lowering response of Febuxostat &amp; Allopurinol in Hyperurecemic patients. The total duration of this trial is 6 months and 5 visits, in each visit we will perform Serum Uric Acid for the evaluation of Urate lowering response.</outcome>
      <timepoint>6 Months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Compare the Drug Tolerability with the treatment of Febuxostat verses Allopurinol in Hyperurecemic patients.

We will perform SGPT and Serum Creatinine for the evaluation of Drug Tolerability.</outcome>
      <timepoint>6 Months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Subjects are capable of giving informed consent
All male or female adult patients between 18 to 65 years age 

All male or female adult patients's Serum Creatinine should be=  or &gt; 2 mg/dl

All patients with Asymptomatic = or &gt; 8 mg/dl of Serum Uric Acid

All patients with Symptomatic =  or &gt; 6.5 mg/dl of Serum Uric Acid

Physician is the final authority to consider the patient, who is eligible for the clinical trial.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Known history of allergic with Febuxostat or Allopurinol
Patient with Ischaemic cardiac disease 
Acute gout 
Renal dysfunction (Serum Creatinine = 4 mg/dL)
Hepatic dysfunction</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>We will enroll the patients who will agree to participate in the trial and meet the Inclusion Criteria. After signing of consent form, we will screen the patients; Visit-1 will be the screening visit and patientâ€™s demographic information, Medical history, Family history, vitals, Lab tests (Serum Uric Acid, SGPT and serum Creatinine) would be performed. 
After screening if the patient will meet the inclusion criteria then we will recruit the patient as per Randomization List (which will be provided to all investigation Sites in Sealed Envelops).</concealment>
    <sequence>Randomization was done by using the following formula on Excel:

Random Number / Total Number of Subjects</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>The Open label, Multicenter, Randomized, 2 arm and Parallel group Study</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/04/2012</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>120</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Pakistan</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>PharmEvo (Pvt.) Ltd.</primarysponsorname>
    <primarysponsoraddress>402, Business Avenue, Main Sharah-e-Faisal, Block-6, PECHS, Karachi-75400, Pakistan.</primarysponsoraddress>
    <primarysponsorcountry>Pakistan</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>PharmEvo (Pvt.) Ltd.</fundingname>
      <fundingaddress>402, Business Avenue, Main Sharah-e-Faisal, Block-6, PECHS, Karachi-75400, Pakistan.</fundingaddress>
      <fundingcountry>Pakistan</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Study Summary
Title
To compare the efficacy &amp; safety profile of Febuxostat with Allopurinol
in local Pakistani hyperuricemic patients.


Protocol Number
GOURIC-OS-01  

Phase:
Phase-IV Study

Methodology:
Open label, Multicenter, Randomized, Parallel group Phase-IV Study

Study Duration:
12 Months

Study Center(s):
Ziauddin University Hospital, Medilink Hospital, JMCH Karachi &amp; North West HospitalPeshawar.

Primary Objective:
Compare the Urate lowering response of Febuxostat &amp; Allopurinol in Hyperurecemic patients 

Secondary Objective:
Compare the Drug Tolerability with the treatment of Febuxostat verses Allopurinol in Hyperurecemic patients 
  
Number of Subjects:
60 patients on Febuxostat and 60 patients on Allopurinol, Total number of subjects = 120

Diagnosis and Main Inclusion Criteria:
All Symptamatic &amp; Asymptamatic patients with = or &gt;8mg/DL of Uric Acid and age should be 18 to 65 years

Study Product, Dose, Route, Regimen:
Febuxostat 40-80 mg Tab Once daily (O.D.) oral or Allopurinol 100-300 mg tablet once daily (O.D.) or as per physician advice.

Duration of Drug administration in study:
6 months

Statistical Methodology:
T- Independent Test</summary>
    <trialwebsite>www.pharmevo.biz</trialwebsite>
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>ERC/IRB National Institute of Blood Disease &amp; Bone Marrow Transplantation</ethicname>
      <ethicaddress>ST-2/A Block 17, Gulshan-e-Iqbal KDA Scheeme 24, Karachi-74800, Pakistan.</ethicaddress>
      <ethicapprovaldate>31/10/2011</ethicapprovaldate>
      <hrec>55229</hrec>
      <ethicsubmitdate>26/09/2011</ethicsubmitdate>
      <ethiccountry>Pakistan</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Muhammad Asif</name>
      <address>402, Business Avenue, Main Shahra-e-Faisal, Block-6, PECHS, Karachi-75400, Pakistan.</address>
      <phone>(+92-21)34315195-7</phone>
      <fax>(+92-21)34556344</fax>
      <email>muhammad.asif@pharmevo.biz</email>
      <country>Pakistan</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Prof. Kamran Hameed</name>
      <address>4/B, Shahrah-e-Ghalib, Block 6, Clifton, Karachi.-75600, Pakistan</address>
      <phone>+92-3322109242</phone>
      <fax>(+92-21)34556344</fax>
      <email>deanzmc@zu.edu.pk</email>
      <country>Pakistan</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Muhammad Asif</name>
      <address>402, Business Avenue, Main Shahra-e-Faisal, Block-6, PECHS, Karachi-75400, Pakistan.</address>
      <phone>(+92)3332158880</phone>
      <fax>(+92-21)34556344</fax>
      <email>muhammad.asif@pharmevo.biz</email>
      <country>Pakistan</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>